Quotient Sciences Expands UK Facilities to Support the Delivery of Translational Pharmaceutics® ProgramsAccess Press Release
Quotient Sciences brought meaningful innovation to the pharmaceutical industry in 2008 with Translational Pharmaceutics – a unique, fully integrated drug development and clinical testing platform, proven to reduce timelines and costs, getting new medicines to patients faster.
By integrating drug substance, drug product, and clinical testing activities all under one organization and a single project manager, Translational Pharmaceutics breaks down traditional industry silos and accelerates molecules through development. This streamlined approach seamlessly supports our customers’ programs across the entire drug development pathway, from candidate development through to commercialization.
Request a copy of our Translational Pharmaceutics white paper.
The Quotient Sciences Translational Pharmaceutics platform has been proven to reduce drug development timelines by over 12 months. Download a copy of the Tufts Center for the Study of Drug Development (CSDD) white paper benchmarking the Translational Pharmaceutics platform versus traditional drug development timelines.
Our expertise in understanding dependencies between drug substance properties, formulation design, and clinical outcomes enables us to enhance development efficiency.
By having both drug substance and drug product manufacturing activities under one organization, we can now deliver integrated chemistry, manufacturing, and controls (CMC) development activities for both pre-clinical and clinical studies in parallel, simplifying the supply chain and shortening the time from candidate selection to clinic by a further 2–4 months.
Key benefits of Translational Pharmaceutics:
Rapid 'make-test' cycles that shorten drug development timelines to days rather than months
Developed in consultation with the UK Medicines and Healthcare products Regulatory Agency (MHRA) and US Food and Drug Administration (FDA), Translational Pharmaceutics employs rapid ‘make-test’ cycles, where drug products are manufactured, released, and dosed in a clinical study in days rather than months, shortening the time to decision-making human data.
Translational Pharmaceutics can assist at each development phase:
The seamless coordination between drug substance and drug product manufacturing results in a more efficient and accelerated development plan. Integrating all activities under a single organization, removing silos, encourages close relationships between multidisciplinary experts and creates a more agile approach to pharmaceutical development. This webinar highlights how a fully integrated program can speed up the transition from candidate selection to proof of concept and shorten the pathway to clinical development.
"Our small biotech company worked with Quotient Sciences on developing a complex formulation and validating the different iterations of the formulation in PK clinical studies using the Translational Pharmaceutics approach. The project was successful, and we were generally impressed by the skillsets, professionalism, and courtesy of the company's scientists and other subject experts. We have also chosen to work with Quotient Sciences on two subsequent projects."
Druggability Technologies (DRGT) is developing DRGT-46 as a novel therapy for pain. Gabor Heltovics, CEO of DRGT, explains how Quotient Sciences enabled the rapid development, clinical assessment, and commercial readiness of its DRGT-46 product using integrated services across Quotient Sciences' network of harmonized development and manufacturing sites in the UK and US.